Make your money go further for just 25p per day

AIM IHT

An unhealthy share price reaction

Failure is success.,,

The share price of Sensyne Health has dived following a disappointing trading update suggesting its survival is in doubt. It will be a shame for AIM to lose an exciting company like this, but we think it probably listed too early. Read our thoughts on this and other news here, including an update from one of our Bonkers Bargains. (Free to read)


Sensyne Health: shares dive on terrible announcement

Sensyne Health (AIM:SENS), the clinical artificial intelligence company founded and run by Lord Drayson, the former Minister for Science, came out with a humdinger of announcement which saw its shares fall 70%.

Sensyne applies clinical AI in the healthcare and life science industries. In healthcare it delivers remote patient monitoring and real-time decision-making systems for healthcare organisations and their patients, while in life sciences…

Sign up and read the full article

Register to continue reading our content.

Get FREE access now

Already a member? Login


Previous article Next article

Have your say

Log in or register to view or add comments.

DON'T MISS OUT!

Get top investment ideas to help safeguard and grow your wealth.

Invaluable insight from the exciting world of smaller companies.

REGISTER FREE

DON'T MISS OUT ON OUR PREMIUM CONTENT

Become a champion investor for just £90 a year. Benefit from our high performing portfolios:

START FREE TRIAL

More on Sensyne Health PLC

An unhealthy share price reaction

14/01/2022 · Company Insights

The share price of Sensyne Health has dived following a disappointing trading update suggesting its survival…


Coronavirus impact: Aim’s healthcare companies firmly in favour

20/04/2020 · Company Insights

The quest to find a test, treatment or vaccine for coronavirus is heating up. Academics and companies…


More on Team17 Group PLC

An unhealthy share price reaction

14/01/2022 · Company Insights

The share price of Sensyne Health has dived following a disappointing trading update suggesting its survival…


Contract awards and a bonkers valuation to kick off 2022

06/01/2022 · Company Insights

It’s been a generaly challenging start to 2022 for AIM, but several companies covered here have…


More Company Insights

AIM Innovators: Creo Medical initiates partnership strategy

AIM Innovators: A future-proof portfolio for stock pickers

21/01/2022

Marlowe: fudging the numbers?

20/01/2022 · Marlowe PLC · Restore PLC

Sign-up to our free email updates

SIGN UP